Researchers have documented 158 drugs in active Alzheimer’s disease clinical trials as of January 1, 2026, spread across 192 ...

Alzheimer’s drug development now targets tau, neuroinflammation, metabolism, and synaptic dysfunction — expanding beyond amyloid toward precision medicine and combination therapy.

Drug development is a complex and time-consuming endeavor that traditionally relies on the experience of drug developers and trial-and-error experimentation. The ...

An annual review of clinical trials for Alzheimer's disease highlights a growing number of active trials—and drugs—in the development pipeline and offers optimism for the global effort to find a cure.

Medical researchers work in a drug development lab in Hefei, Anhui province, on Oct 17. CHINA DAILY While the global ...

The prevalence of Alzheimer’s disease (AD) is growing rapidly. The global population of individuals with AD dementia is anticipated to increase from the current 57 million to 153 million by 2050 1.

AstraZeneca CEO Pascal Soriot said AI is helping the company develop medicines faster and make smarter decisions throughout ...

Experienced Neuropsychiatry Drug Development Leader Joins Syremis’ Executive Team Ahead of Key Pipeline Milestones TEL AVIV & BOSTON--(BUSINESS WIRE) ...

Regeneron's EYLEA HD US sales surged 52% in Q1 2026, offsetting competitive pressures and patient switching within the EYLEA ...

After decades of frustration and failure, the landscape of drug development for Alzheimer’s disease (AD) is starting to shift beyond anti-amyloids. Fueled by a growing pipeline of investigational ...

CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, June 15, 2026 /PRNewswire/ -- Harbour BioMed (HKEX: 02142.HK), a global biopharmaceutical company committed to the discovery and development of ...

Discover outperforming stocks and invest smarter with Top Smart Score Stocks Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener Shanghai Junshi ...